Tag Archives: Lilly

EASD: Lilly, BI tout new Jardiance kidney analysis as rival J&J nears FDA nod

BARCELONA—Eli Lilly and Boehringer Ingelheim, eager to keep pace with rivals, are out with new Jardiance kidney disease data in a patient population they say mirrors the one that could soon score Johnson & Johnson’s Invokana a new nod. Tuesday at the European Association for the Study of Diabetes annual meeting, the partners presented results showing… Read More »